Ruud Wijdeven
Study Director
My group uses screening technology to identify novel, targetable disease mechanisms and biomarkers for neurological disorders. We have set-up genome-wide CRISPR-based screening approaches and use these in combination with cellular model systems to: 1) understand the function of unstudied proteins highly abundant in neurodegenerative disorders, 2) uncover novel disease mechanisms, and 3) identify how disease-related processes in brain cells can be reverted.